Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188-Re

2530 Background: Intralesional radioimmunotherapy (RIT) may improve the management of malignant gliomas. Current treatments modalities cannot prevent tumor recurrence. A clinical trial was performed to evaluate the toxicity, the maximal tolerated dose (MTD), dosimetry, biodistribution and any clinical effect after RIT using the humanized MAb, h-R3, labeled with188-Re. Methods: A Phase I dose escalation trial was performed by administrating into the post-operative cavity through an indwelling catheter a single dose of the h-R3 MAb directed against epidermal growth factor receptors (EGFR). The study was approved by the CIREN Ethics Committee. All patients had partial tumor resections and over-expressed the EGFR. One patient with anaplastic astrocytoma (AA) and 4 with glioblastoma multiforme (GBM) were treated with 3 mg of MAb labeled with 10 or 15 mCi of 188-Re. Patients signed a written informed consent. Results: Transitory acute side effects following treatment were headache, seizures, and worsening of pr...